Imaging: Prostate Cancer VL

First Standardized Framework Measuring PSMA PET/CT Response in Metastatic Castration‑Resistant Prostate Cancer - Wolfgang Fendler and Andrei Gafita

Details
Wolfgang Fendler and Andrei Gafita join Phillip Koo in a discussion on the Journal of Nuclear Medicine publication "Measuring response in metastatic castration‑resistant prostate cancer using PSMA PET/CT: comparison of RECIST 1.1, aPCWG3, aPERCIST, PPP, and RECIP 1.0 criteria". This study received partial funding from the Prostate Cancer Foundation (PCF). In order to move PSMA PET forward and shif...

Incorporating Molecular Testing into Clinical Practice for Prostate Cancer - Elena Castro & Collin Pritchard

Details
Colin Pritchard and Elena Castro join Alicia Morgans in a conversation on incorporating molecular testing into our treatment paradigms for men with prostate cancer. There is a need to optimize testing, to eliminate any burdens to practicing clinicians in their daily work. Drs. Pritchard, Castro, and Morgans also discuss tissue-based and blood-based tests and overcoming the challenges of getting ti...

Future Perspectives in Prostate Imaging in Developing Countries - Ronaldo Hueb Baroni

Details
Ronaldo Baroni joins Phillip Koo at the 13th Uro-Oncology Congress in São Paulo, Brazil in a discussion highlighting Dr Baroni's lecture he gave on future perspectives in prostate imaging. Prostate MRI is already established as the standard modality for prostate detection prior to biopsy. Future perspectives include more rational and widespread use of prostate MRI including a more widely available...

Radiotherapy Guided by PSMA PET Molecular Imaging - Juan Galvis Serrano

Details
Radiation Oncologist, Juan Galvis Serrano joins Phillip Koo for a presentation and discussion on radiotherapy guided by PET PSMA. We are still defining its role in guiding radiotherapy treatment plans but PET-PSMA has shown a higher sensitivity than conventional methods with stable sensitivity and higher specificity. Dr. Galvis Serrano shares a study conducted at his institution with prostate canc...

Higher Rates of Metastatic Disease on PSMA PET for Biochemical Recurrence Risk Groups, Journal Club - Christopher Wallis & Zachary Klaassen

Details
Christopher Wallis and Zachary Klaassen highlight the Journal of Nuclear Medicine article titled "PSMA PET Validates Higher Rates of Metastatic Disease for European Association of Urology Biochemical Recurrence Risk Groups: an international multicenter study." The authors' findings support the new EAU classification for biochemically recurrent prostate cancer (BCR), that BCR high-risk groups have...

Results from the Phase 3 SPOTLIGHT Trial of 18F-rhPSMA-7.3 in Recurrent Prostate Cancer - David Schuster

Details
David Schuster joins Phillip Koo in discussing the results of SPOTLIGHT, a phase 3, prospective, multicenter study assessing the detection rate of 18F-rhPSMA-7.3 PET in patients with suspected prostate cancer recurrence. The single-arm SPOTLIGHT imaging study, conducted in the United States and Europe evaluates the safety and diagnostic performance of 18F-rhPSMA-7.3 PET imaging in men with suspect...

The Impact of Imaging and Therapeutics Advances in Nonmetastatic Castration-Resistant Prostate Cancer - David Penson

Details
David Penson joins Alicia Morgans to discuss the rapidly changing landscape in prostate cancer, focusing on how imaging and therapeutic advances have disrupted the landscape in the nonmetastatic castration-resistant prostate cancer (CRPC) setting. Dr. Penson highlights advancements in PSMA scanning and how it impacts potential study inclusion criteria. Drs. Morgans and Penson also discuss PSMA PET...

Clinical Trial Equity in Radionuclide Treatment for Prostate Cancer - Joseph Osborne

Details
Phillip Koo is joined by Joseph Osborne to provide a nuclear radiologist's perspective on the equity in prostate cancer clinical trials. Dr. Osborne focuses his talk on three different aspects of clinical trial equity for prostate cancer: Progress, Evolution, and Goals. He also details the Rad Health Equity Lab, created at Weill Cornell to improve access to radiology and bring awareness to health...

PSMA PET/CT Imaging Indications in Prostate Cancer - Phillip Koo, Neal Shore, & Oliver Sartor

Details
Phillip Koo, Oliver Sartor, and Neal Shore discuss indications for PSMA PET/CT molecular imaging in patients with prostate cancer. Dr. Koo gives a background on PSMA PET/CT agents and breaks down indications into the two different patient subsets: patients with suspected metastasis who are candidates for initial definitive therapy and patients who have suspected recurrence based on elevated serum...

NCCN Guidelines On PSMA Molecular Imaging - Tanya Dorff

Details
Alicia Morgans and Tanya Dorff, discuss the updates to the NCCN guidelines since the approval of PSMA PET CT molecular imaging agents. They discuss new guidance based on the FDA-approved indications in the labels for the use of molecular imaging agents for detecting prostate cancer when PSA levels are still relatively low and when PSA levels are rising. Biographies: Tanya B. Dorff, MD., is an asso...
email news signup